Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725840 | 0.89 | HTR6 (0.57) | HTR6BRAFHDAC3HDAC4HDAC1 | |
| SCHEMBL1725866 | 0.89 | HTR6 (0.71) | HTR6 | |
| Hydrochloric Acid SCHEMBL1611695 | 0.88 | HTR6 (0.56) | HTR6BRAFHDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL1611917 | 0.88 | HTR6 (0.70) | HTR6 | |
| SCHEMBL1726996 | 0.86 | HTR6 (0.53) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1726179 | 0.86 | HTR6 (0.54) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7898337 | 0.86 | HTR6 (0.67) | HTR6 | |
| Hydrochloric Acid SCHEMBL3724202 | 0.85 | HTR6 (0.66) | HTR6 | |
| Hydrochloric Acid SCHEMBL1611862 | 0.85 | HTR6 (0.54) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL1611763 | 0.85 | HTR6 (0.52) | HTR6HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163279-A3 | LOW-POWER WIRELESSLY-LINKED RFID TRACKING SYSTEM | ROSE MARK D (US) | 2012-05-10 | — | — | WO | claimed |
| EP-2217583-B1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-11-30 | — | — | EP | claimed |
| WO-2011163279-A3 | LOW-POWER WIRELESSLY-LINKED RFID TRACKING SYSTEM | ROSE MARK D (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2217583-B1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-20110086863-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7790727-B2 | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-2217583-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090131452-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009056632-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131452-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR1B | HTR6 1/4885BRAF 555/4885HDAC3 3183/4885 |
| US-20110086863-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR1B | HTR6 1/4885BRAF 541/4885HDAC3 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.